Big News for unbuzzd™ Quantum BioPharma is pleased to announce the appointment of visionary entrepreneur Michael “Zappy” Zapolin as CEO of Unbuzzd Wellness Inc. From Wall Street to pioneering internet ventures and next-generation wellness, Zappy brings decades of entrepreneurial experience, brand-building expertise and an extensive network to unbuzzd. His mandate: help finance and list Unbuzzd on a stock exchange and lead the execution of a nationwide U.S. commercial marketing and product rollout. Science-backed. Clinically validated. Built for a massive consumer opportunity. unbuzzd™ is backed by a peer-reviewed clinical study supporting its ability to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. As Zappy puts it: “I believe unbuzzd has the potential to help millions of lives, and I’m honored to help bring it forward.” The next chapter of unbuzzd™ starts now. 🌐 Discover unbuzzd: unbuzzd.com 📈 Quantum BioPharma Ltd. — NASDAQ: QNTM | FRA: 0K91 Advancing Science. Saving Lives. #QuantumBioPharma #QNTM #unbuzzd #ZappyZapolin #Wellness #FunctionalBeverage #AlcoholRecovery #ConsumerHealth #Innovation #Biotech #NASDAQ

🚀 NEW ANALYST COVERAGE FOR QUANTUM BIOPHARMA Quantum BioPharma Ltd. (NASDAQ: QNTM) is pleased to announce that Rodman & Renshaw has initiated analyst coverage of the Company with a BUY rating and a US$8 price target. This new coverage comes as Quantum BioPharma continues advancing its innovative therapeutic pipeline and pursuing its mission to develop transformative treatments in areas of significant unmet medical need. 🧬 BUY Rating 🎯 US$8 Price Target 📈 Independent Analyst Coverage 🔬 Advancing a Next-Generation Therapeutic Pipeline The future of medicine starts with bold science. Quantum BioPharma — Advancing Science. Saving Lives. #QuantumBioPharma #QNTM #NASDAQ #Biotech #Biopharma #LifeSciences #HealthcareInnovation #DrugDevelopment #ClinicalResearch #Investing #Neurodegeneration

Quantum BioPharma is heading to the ArcStone-Kingswood Growth Summit 2026 in Toronto! 🇨🇦 Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) is pleased to participate in the 3rd Annual ArcStone-Kingswood Growth Summit on September 16, 2026, at the Sheraton Centre Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman, will present Quantum BioPharma’s recent milestones and future growth strategy to investors, family offices and capital markets professionals. The presentation comes at an important time for Quantum BioPharma following the FDA’s approval of the Investigational New Drug (IND) application for Lucid-MS, allowing the Company to advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical trials in patients with progressive MS. 📍 Toronto, Ontario 📅 September 16, 2026 🏨 Sheraton Centre Toronto Hotel Interested investors can register for a FREE PASS: meetmax.com/sched/event_1440… #QuantumBioPharma #QNTM #NASDAQ #LucidMS #MultipleSclerosis #Biotech #Biopharma #ClinicalTrials #Investing #HealthcareInnovation #ArcStoneKingswood #Toronto

Quantum BioPharma (NASDAQ: QNTM). The company is advancing Lucid-21-302, a novel oral therapeutic candidate targeting protein arginine deiminase, or PAD, biology in multiple sclerosis. The program offers a differentiated approach centered on neuroprotection and myelin preservation, with several important development milestones ahead. Please reach out directly or at mking@rodm.com to request the full initiation report. More to come. #EquityResearch #Biotech #QNTM #MultipleSclerosis #HealthcareInvesting #CapitalMarkets

3rd Party Article Mentioning Quantum BioPharma & Lucid-MS @neurology_live neurologylive.com/view/fda-c… $QNTM #Biotech #NASDAQ #Demyelination #Multiplesclerosis

Thank you @Brandon_Beaber & @neurology_live for mentioning Lucid-MS. Quantum BioPharma is very grateful for your support and mentions. #Biotech #FDA #MultipleSclerosis #MSAwareness

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial globenewswire.com/news-relea… $QNTM #QNTM #QuantumBioPharma #Biotech #BiotechStocks #HealthcareStocks #PharmaStocks #SmallCapStocks #NASDAQ #StockMarket #Stocks #Investing #FDA #FDAClearance #ClinicalTrials #Phase2 #MultipleSclerosis #MSResearch #ProgressiveMS #Neuroprotection #Demyelination #LifeSciences #DrugDevelopment #Biotechnology #HealthTech #InvestorNews

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide globenewswire.com/news-relea… $QNTM #Multiplesclerosis #Biotech #NASDAQ #FDA #MSawareness #MS #Neurodegenerative #Demyelination

BioMedWire Podcast: Anthony Durkacz, Exec. Co-Chair of Quantum BioPharma $QNTM June 02 , 2026. Recap. piped.video/watch?app=deskto… #Biotech #Nasdaq #Multiplesclerosis #MS #Neurodegenerative #Disease #Demyelination

Thank you, Dr. Brandon Beaber, for taking the time to review LUCID-MS and explain the scientific rationale being investigated in multiple sclerosis. We appreciate your thoughtful, independent perspective and your work making emerging MS research accessible. #MSawareness #Multiplesclerosis $QNTM

Most MS therapies modulate immunity. Quantum BioPharma’s investigational Lucid-MS is designed to address citrullination and myelin integrity through a differentiated, non-immunosuppressive approach. Learn more: quantumbiopharma.com/lucid-m… $QNTM #MultipleSclerosis #Nasdaq #MSWarriors #Neurology #Neurodegenerative

Our Spinoff Partners @getunbuzzd have launched a brand new website unbuzzd.com check it out $QNTM #Biotech #AlcoholRecovery #Beverage

Reframing MS starts with looking beyond the traditional autoimmune lens. Quantum BioPharma’s Lucid-MS program is exploring neurodegenerative biology, myelin-related mechanisms, and a non-immunomodulatory research approach in multiple sclerosis. Visit quantumbiopharma.com for more info. $QNTM #Nasdaq

#MSawareness #Multiplesclerosis

Multiple sclerosis remains a major unmet medical challenge. Quantum BioPharma's investigational drug candidate, Lucid-MS, is a new chemical entity (NCE) being developed to target citrullination-driven demyelination through a non-immunosuppressive and non-immunomodulatory approach. Research suggests excessive citrullination may alter myelin proteins and contribute to myelin damage, impacting nerve signaling. ✅ Novel mechanism under investigation ✅ Focused on demyelination biology ✅ Addressing an important unmet need in MS research Lucid-MS is investigational and not approved by the FDA or Health Canada. $QNTM #MultipleSclerosis #MSResearch #Biotech #Neuroscience #DrugDevelopment #ClinicalTrials #HealthcareInnovation quantumbiopharma.com

Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis. Phase 1 complete. IND submitted for Phase 2 trial design. Lucid-MS is investigational and not approved by FDA or Health Canada. Sign up for email alerts : quantumbiopharma.com/email-a… #Biotech #MultipleSclerosis #Demyelination $QNTM

Quantum BioPharma $QNTM is featured on The BioMedWire Podcast. Anthony Durkacz (@AnthonyDurkacz ) discusses Lucid-MS, multiple sclerosis research, unbuzzd™, and key 2026 milestones. Watch the full episode: piped.video/watch?v=clA0PZNf… #QNTM #QuantumBioPharma #LucidMS #BiotechStocks #MultipleSclerosis

#MSwalk #MSawareness